Skip to content

Sumac review reports improved blood sugar and lipid markers

Short trials found changes in metabolic risk markers, while inflammation and other cardiovascular risk factors showed no statistically significant improvement.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

Across the included trials, sumac supplements improved blood sugar and blood lipid measures compared with placebo. Other cardiovascular risk factors did not show statistically significant changes, including inflammatory markers. These are findings about risk markers over a short study period; the abstract does not report whether supplementation prevented heart attacks or other cardiovascular events.

Keep in mind

The abstract gives no individual outcome estimates, confidence intervals, doses or participant health profiles. It therefore cannot establish the size or clinical importance of the reported changes, or identify an optimal dose or duration.

THE RESULT, WITH CONTEXT

What researchers found

Statistically significant improvements

Blood sugar and blood lipid profiles

Sumac versus placebo over 4–12 weeks. Changes were pooled as standardized mean differences; numerical estimates were not provided.

Endocrinol Diabetes Metab, 2026 · Original source ↓

What the review assessed

Researchers combined randomized trials to examine body measurements, blood sugar, blood lipids and inflammatory markers. They also explored whether dose and treatment length related to outcomes, but the abstract provides no dose-response results.

What the findings can establish

The improvements concern laboratory risk markers, with no numerical estimates to show their size or practical importance. Nonsignificant findings for other measures leave uncertainty as well; they do not prove that sumac has no effect.

CHECK THE ORIGINAL

The original publication

Sumac (Rhus coriaria L.) and Human Metabolic Health: A Systematic Review and Meta-Analysis.

Jafari A, ParsiNezhad B, AhmadianMoghaddam M et al.
Endocrinol Diabetes Metab · 2026

PubMed ID
41329614
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.